Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
BioCardia, Inc. (BCDA) stock declined over -0.34% intraday to trade at $1.49 a share on NASDAQ. The stock opened with a loss of -3.87% at $1.54 and touched an intraday high of $1.54, falling -0.00% against the last close of $1.49. The stock went to a low of $1.45 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $1.54 | $1.54 | $1.45 | $1.485 | 47,120 |
2022-07-05 | $1.55 | $1.55 | $1.45 | $1.49 | 28,600 |
2022-07-01 | $1.42 | $1.5 | $1.42 | $1.46 | 37,400 |
2022-06-30 | $1.39 | $1.52 | $1.39 | $1.45 | 17,700 |
2022-06-29 | $1.32 | $1.48 | $1.31 | $1.44 | 52,500 |
2022-06-28 | $1.45 | $1.53 | $1.4 | $1.43 | 78,000 |
2022-06-27 | $1.4 | $1.5 | $1.37 | $1.45 | 17,200 |
2022-06-24 | $1.5 | $1.54 | $1.34 | $1.42 | 51,900 |
2022-06-23 | $1.55 | $1.55 | $1.46 | $1.47 | 23,800 |
2022-06-22 | $1.42 | $1.5 | $1.32 | $1.5 | 73,700 |
Employees-
Beta1.44
Sales or Revenue1.01 Million
5Y Sales Change12.00%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
BioCardia, Inc. (NASDAQ: BCDA) stock price is $1.49 as of the last check on Wednesday, July 6. During the trading session, BCDA stock reached the peak price of $1.54 while $1.45 was the lowest point it dropped to.
The NASDAQ listed BCDA is part of Biotechnology industry that operates in the broader Health Care sector. BioCardia, Inc. , a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases.
Dr. Peter A. Altman Ph.D.
CEO, Pres & Director
Mr. David McClung
Chief Financial Officer
Mr. Edward M. Gillis
Sr. VP of Devices
Dr. Ian McNiece Ph.D.
Chief Scientific Officer
BCDA stock traded closed the last session at $1.485, which is $0.00 or -0.34% lower than its previous close of $1.49. BCDA's current trading price is 34.99% lower than its 52-week high of $3.96 where as its distance from 52-week low of 1.10% is -62.50%.
Number of BCDA employees currently stands at -. BCDA operates from 320 Soquel Way, Sunnyvale, CA 94085, United States.
Official Webiste of $BCDA is: https://www.biocardia.com
BCDA could be contacted at BCDA operates from 320 Soquel Way, Sunnyvale, CA 94085, United States, or at phone #650 226 0120 and can also be accessed through its website.
BCDA stock volume for the day was 47,120 shares while in the previous session number of BCDA shares traded was 47,120 . The average number of BCDA shares traded daily for last 3 months was 706.56 Thousands.
The percentage change in BCDA stock occurred in the recent session was -0.34% while the dollar amount for the price change in BCDA stock was $0.00.
In the recent session, the day high for BCDA stock was $1.54 while the low for BCDA stock touched on the day was $1.45.
The market value of BCDA currently stands at 25.74 Million with its latest stock price at $1.49 and 17.07 Million of its shares outstanding.